Erschienen in:
01.01.2015 | Original paper
Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial
verfasst von:
Siobhan Sutcliffe, Cathee Till, Frank J. Jenkins, Charlotte A. Gaydos, Phyllis J. Goodman, Ashraful M. Hoque, Ann W. Hsing, Ian M. Thompson, William G. Nelson, Angelo M. De Marzo, Elizabeth A. Platz
Erschienen in:
Cancer Causes & Control
|
Ausgabe 1/2015
Einloggen, um Zugang zu erhalten
Abstract
Background
Human herpesvirus type 8 (HHV-8), a gamma herpesvirus associated with Kaposi’s sarcoma, has been proposed as a candidate risk factor for prostate cancer (PCa) because of its detection in benign and malignant prostate specimens, and its relation with histologic prostatic inflammation. We investigated the possible relation between pre-diagnostic HHV-8 infection and PCa risk in a case–control study sampled from the placebo arm of the Prostate Cancer Prevention Trial.
Methods
We defined cases as men with a confirmed diagnosis of PCa after visit 2 (n = 315) and controls as men not diagnosed with PCa during the trial who also had a negative end-of-study prostate biopsy (n = 315). We tested sera from visit 2 for IgG antibodies against HHV-8 using a monoclonal antibody-enhanced immunofluorescence assay against multiple lytic HHV-8 antigens.
Results
The adjusted seroprevalence of HHV-8 infection was 11.6 % for cases and 11.0 % for controls (p = 0.81). No association was observed between HHV-8 seropositivity and PCa risk (OR 1.06, 95 % CI 0.65–1.76).
Conclusion
Our findings of a null association between HHV-8 seropositivity and PCa risk do not support an association between HHV-8 infection and PCa development, consistent with the general tendency of the epidemiologic literature to date.